ArticleNature2023
RHOJ controls EMT-associated resistance to chemotherapy.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers.
0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed
41.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 181 citations in OpenAlex.
- The CaThe Journal of biological chemistry · 2026Article
- Adaptive epithelial-mesenchymal bi-directional transition: A key invasive plasticity for tumor metastasis.iScience · 2026Review
- Role of epithelial-mesenchymal transition (EMT) in malignancies: current status and future prospects.Signal transduction and targeted therapy · 2026Review
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Multi-Omics Analysis Identifies Tryptophan Metabolism and Glycolysis as Potential Pathways Involved in the Protective Effects of Tormentic Acid Against Metabolic Associated Fatty Liver Disease.Pharmacology research & perspectives · 2026Article
- LTB4R inhibits apoptosis and induces radiosensitivity by promoting the PI3K/AKT pathway in esophageal squamous cell carcinoma.Journal of thoracic disease · 2026Article
- Spatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumours and breast cancer.Nature communications · 2026Article
- C/EBPγ induces epithelial-mesenchymal transition and facilitates DNA double-strand break repair in lung adenocarcinoma cells.Cell death discovery · 2026Article
- Advances in the molecular mechanisms and clinical applications of LEMD1 in tumor development and progression (Review).Molecular and clinical oncology · 2026Review
- Rho GTPases in cancer resistance: mechanisms, vulnerabilities, and therapeutic opportunities.Biochemical Society transactions · 2026Review
- Recurrence in the chemotherapy regimen of bladder carcinoma originates from quiescent epidermoid-like cells.Nature communications · 2026Article
- Bound for the nucleus: defining the molecular principles of cargo selection by importin 9.bioRxiv : the preprint server for biology · 2026Article
- Disrupting SOX2 self-association and condensate formation to overcome chemotherapeutic drug resistance in lung squamous cell carcinoma.Signal transduction and targeted therapy · 2026Article
- SPOP-mediated K27-linked non-degradative ubiquitination of KCNN3 suppressing HCC progression via the CTCF-SATB1 axis.Cell death & disease · 2026Article
- Acquired resistance of cancer therapies: Mechanisms and perspectives.Chinese medical journal · 2026Review
- Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance.Journal of experimental & clinical cancer research : CR · 2026Review
- CALR/HIF-1α Positive Feedback Loop Drives CALR Upregulation to Promote EMT-Mediated Bladder Cancer Progression via ROS/AKT Axis.Cancer science · 2026Article
- HDAC8-mediated CAPZB desuccinylation enhances cytoskeleton remodeling to promote idiopathic pulmonary fibrosis.Communications biology · 2026Article
- RETN and BMP2 as potential biomarkers for prognosis and immune landscape in lung squamous cell carcinoma: from bioinformatics to clinical validation.Scientific reports · 2026Article
- EMT and cell cycle control invadopodia and metastasis in breast cancer via Filip1L.Research square · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 4 institutions in 3 countries.
Maud DebaugniesLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Sara Rodríguez-AcebesDNA Replication Group, Molecular Oncology Programme, Spanish National Cancer Research Centre, Madrid, Spain.ORCID http://orcid.org/0000-0002-9867-7591
Jeremy BlondeauLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Marie-Astrid ParentLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Manuel ZoccoLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Yura SongLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Viviane de MaertelaerInstitute of Interdisciplinary Research (IRIBHM), Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID http://orcid.org/0000-0001-6722-7267
Virginie MoersLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Mathilde LatilLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Christine DuboisLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Katia CoulonvalInstitute of Interdisciplinary Research (IRIBHM), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Francis ImpensVIB Center for Medical Biotechnology, VIB Proteomics Core, Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0003-2886-9616
Delphi Van HaverVIB Center for Medical Biotechnology, VIB Proteomics Core, Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0002-4659-5631
Sara DufourVIB Center for Medical Biotechnology, VIB Proteomics Core, Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0003-2036-7849
Akiyoshi UemuraDepartment of Retinal Vascular Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID http://orcid.org/0000-0001-5574-5470
Panagiota A SotiropoulouLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium.
Juan MéndezDNA Replication Group, Molecular Oncology Programme, Spanish National Cancer Research Centre, Madrid, Spain.ORCID http://orcid.org/0000-0002-3235-2559
Cédric BlanpainLaboratory of Stem Cells and Cancer, Université Libre de Buxelles (ULB), Brussels, Belgium. Cedric.Blanpain@ulb.be.ORCID http://orcid.org/0000-0002-4028-4322
Université Libre de Bruxelles · BEGhent University · BESpanish National Cancer Research Centre · ESNagoya City University · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
The resistance of cancer cells to therapy is responsible for the death of most patients with cancer
Indexed as
Carcinoma, Squamous CellDrug Resistance, NeoplasmEpithelial-Mesenchymal Transitionrho GTP-Binding ProteinsSkin NeoplasmsActinsAnimalsCell Line, TumorGene Expression ProfilingGenomeMiceProteomicsActinsrho GTP-Binding ProteinsRhoj protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.